Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Leerink Partners

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by investment analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a report released on Wednesday,Finviz reports. The firm presently has a $834.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $762.00. Leerink Partners’ price objective would indicate a potential upside of 19.65% from the company’s current price.

Other analysts have also recently issued reports about the stock. Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday. Evercore ISI decreased their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $982.43.

Regeneron Pharmaceuticals Stock Performance

REGN opened at $697.05 on Wednesday. Regeneron Pharmaceuticals has a 12-month low of $642.00 and a 12-month high of $1,211.20. The company has a market cap of $76.60 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 1.60 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company’s 50 day moving average is $719.16 and its 200 day moving average is $918.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. Regeneron Pharmaceuticals’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.86 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals will post 37.75 EPS for the current year.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $26,000. Fairfield Financial Advisors LTD purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $37,000. Private Wealth Management Group LLC increased its position in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.